Contributors

Medical Services Companies Showing Strong Earnings

May 31, 2013 TM Richards 0

Healthcare has been one of the hottest sectors over the past year. This can be seen by looking at various ETFs such as iShares Dow Jones US Healthcare (IYH). This particular ETF has appreciated by approximately 35% over the past 52 weeks which is significantly higher than the 27% appreciation that the S&P Depository Receipts (SPY) has given investors. Now the healthcare sector is built up of many smaller industries and this article will focus on medical services companies which have produced strong quarterly results.

No Image

Amedisys Shares Are Too Pricey For A Declining Business: Looking for Single Digits

March 15, 2013 Jake King 0

Amedisys, Inc. (AMED) reported 4Q and year-end earnings Tuesday, March 12, and the key highlight was the company’s 2013 EPS guidance range of $0.60-$0.70, substantially below the Street’s $0.77 estimate. Analysts EPS estimates were lowered when the company reported its third quarter 2012 earnings miss (2013 EPS forecasts back then called for $0.93 a share), hence, the business continues to deteriorate and the earnings trough has not yet been reached.

Acadia Forges Forward With Pimavanserin

March 14, 2013 Jason Napodano 0

On March 12, 2013, Acadia Pharmaceuticals (ACAD) reported financial results for the fourth quarter and full year 2012. Total revenues in the quarter were $0.4 million, essentially in-line with our estimate of $0.3 million. Revenues consisted of collaborative payments from Allergan, Inc. (AGN) and other collaboration partners. For the full year 2012, total revenues were $4.9 million.

Word on the Street:The Buy-Side View for 2013

February 21, 2013 Lisa Sher 0

The BIO CEO Investor Conference remains one of the most important events for companies, investors and industry executives to explore partnerships, raise capital, network or simply gain some useful, fresh insight from industry experts. Monday’s opening Plenary Session, Word on the Street–Buy Side View for 2013, was informative and featured some of the industry’s most respected names.

March 2013: Santarus’ Uceris – Ulcerative Colitis

February 11, 2013 Vanessa Lane 0

Last month, Santarus, Inc’s Uceris for ulcerative colitis received FDA approval, and the company has announced a planned launch in March 2013. Santaurs has already begun adding 85 new positions to its sales staff in anticipation of Uceris’ future. The Uceris approval hopes to promise strong returns for a company with a checkered past, but a promising future.